Europe — EMA
Nintedanib Teva
Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic…
Request sourcing
What is Nintedanib?
Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination with docetaxel for non‑small cell lung cancer. The medication works by blocking multiple growth factor receptors that drive fibrotic tissue formation, thereby helping to preserve lung function.
GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Nintedanib used for?
Nintedanib acts on fibrotic lung disease pathways and on tumor angiogenesis when combined with chemotherapy.
Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. Systemic sclerosis‑associated interstitial lung disease: improves lung capacity and delays worsening. Non‑small cell lung cancer (with docetaxel): enhances response rates and prolongs survival when used as part of combination therapy.
